On Jul. 27, 2022, Pfizer and BioNTech announced that the companies had initiated a randomized, active-controlled, observer-blind, Phase…
On Jul. 26, 2022, Novavax announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had received expanded manufacturing and marketing approval…
On Jul. 26, 2022, Novavax announced that the Australian Therapeutic Goods Agency had granted expanded approval for provisional…
COVID-19 Vacations Redux iIlustrates once again the pits and perils vacation travelers face as they begin their Summer…
On Jul. 22, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
On Jul. 21, 2022, The New York State Department of Health confirmed that a case of paralytic poliomyelitis…
On Jul. 19, 2022, Novavax announced that it had signed agreements with its partner, SK bioscience, for the…
On Jul. 19, 2022, the NIH announced that although COVID-19 booster vaccinations in adults elicit high levels of…
On Jul. 19, 2022, Novavax announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee…
On Jul. 19, 2022, Yale scientists announced they had developed a novel Omicron-specific mRNA vaccine that offers superior…
On Jul. 18, 2022, Moderna announced that the Therapeutic Goods Administration (TGA) in Australia had granted provisional registration…
On Jul. 15, 2022, The largest sustained decline in childhood vaccinations in approximately 30 years has been recorded…
On Jul. 14, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
On Jul. 13, 2022, Novavax announced that its COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) had received emergency use authorization from…
On Jul. 13, 2022, Novavax announced that the European Commission (EC) had approved the expanded conditional marketing authorization…
On Jul. 11, 2022, Novavax announced an agreement with the U.S. Department of Health and Human Services (HHS),…
On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial…
On Jul. 11, 2022, Moderna announced new clinical data on its bivalent Omicron (BA.1) booster candidate, mRNA-1273.214. One…
On Jul. 8, 2022, Pfizer and BioNTech announced that the companies had submitted a variation to the European…
On Jul. 8, 2022, the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) confirmed the…
On Jul. 7, 2022, Novavax announced that the European Commission had approved a variation to allow SK bioscience…
On Jul. 5, 2022, Novavax announced that the European Commission (EC) had approved the expanded conditional marketing authorization…
On Jul. 5, 2022, Tgen and Northern Arizona University announced that a research team found that the vaccine…
On Jun. 28, 2022, the National Institutes of Health (NIH) announced that a Phase 1 clinical trial of…
Play the COVID-19 Wheel of Fortune and see how lucky you are! You have two wheels to choose…
On Jun. 24 2022, Pfizer and BioNTech announced positive data evaluating the safety, tolerability, and immunogenicity of two…
On Jun. 23, 2022, BioNTech announced it had reached a milestone in the establishment of scalable mRNA vaccine…
On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
On Jun. 23 2022, Novavax announced the filing of a Supplement to a New Drug Submission with Health…
On Jun. 23 2022, Novavax announced that the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional…